Longeveron (LGVN) Net Margin Growth (3y) (2023 - 2026)

Longeveron (LGVN) Net Margin Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 9,283.00
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 506.00
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -569.00
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 6,537.00
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Longeveron 3.97 Mn -11.79 Mn 264,000.00 1.39 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 1.39 Mn
Dec 31, 2025 219,196.00
Sep 30, 2025 -2,680.00
Jun 30, 2025 -53,470.00
Mar 31, 2025 -38,370.00
Dec 31, 2024 -2.22 Mn
Sep 30, 2024 928,190.00
Jun 30, 2024 155,693.00
Mar 31, 2024 438,777.00
Sep 30, 2023 -388,394.00
Jun 30, 2023 -218,339.00
Mar 31, 2023 -1.53 Mn